Skip to main content

Dostarlimab Pregnancy and Breastfeeding Warnings

Brand names: Jemperli

Medically reviewed by Last updated on Jun 11, 2024.

Dostarlimab Pregnancy Warnings

Use is not recommended.

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.

Risk Summary: Based on its mechanism of action, this drug can cause fetal harm when administered during pregnancy.

-Human IgG4 is known to cross placental barrier, therefore this drug has the potential to be transmitted from mother to the developing fetus.
-Verify negative pregnancy status in females of reproductive potential prior to initiating therapy.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
-Advise females of reproductive potential to use effective contraception during therapy and for 4 months after the last dose.

Animal studies have revealed that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. There are no controlled data in human pregnancy.

AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

See references

Dostarlimab Breastfeeding Warnings

Breastfeeding is not recommended during use of this drug and for at least 4 months after the last dose.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

-The effects in the nursing infant are unknown.
-Maternal IGs are known to be excreted in human milk.
-Since this drug has a potential to cause serious adverse effects in adults, breastfeeding is not recommended during use.

See references

References for pregnancy information

  1. (2021) "Product Information. Jemperli (dostarlimab)." GlaxoSmithKline
  2. (2022) "Product Information. Jemperli (dostarlimab)." GlaxoSmithKline Australia Pty Ltd

References for breastfeeding information

  1. (2021) "Product Information. Jemperli (dostarlimab)." GlaxoSmithKline
  2. (2022) "Product Information. Jemperli (dostarlimab)." GlaxoSmithKline Australia Pty Ltd

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.